Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis

Abstract

Patients with ESRD have high rates of depression, which is associated with diminished quality of life and survival. We determined whether individual cognitive behavioral therapy (CBT) reduces depression in hemodialysis patients with elevated depressive affect in a randomized crossover trial. Of 65 participants enrolled from two dialysis centers in New York, 59 completed the study and were assigned to the treatment-first group (n=33) or the wait-list control group (n=26). In the intervention phase, CBT was administered chairside during dialysis treatments for 3 months; participants were assessed 3 and 6 months after randomization. Compared with the wait-list group, the treatment-first group achieved significantly larger reductions in Beck Depression Inventory II (self-reported, P=0.03) and Hamilton Depression Rating Scale (clinician-reported, P<0.001) scores after intervention. Mean scores for the treatment-first group did not change significantly at the 3-month follow-up. Among participants with depression diagnosed at baseline, 89% in the treatment-first group were not depressed at the end of treatment compared with 38% in the wait-list group (Fisher's exact test, P=0.01). Furthermore, the treatment-first group experienced greater improvements in quality of life, assessed with the Kidney Disease Quality of Life Short Form (P=0.04), and interdialytic weight gain (P=0.002) than the wait-list group, although no effect on compliance was evident at follow-up. In summary, CBT led to significant improvements in depression, quality of life, and prescription compliance in this trial, and studies should be undertaken to assess the long-term effects of CBT on morbidity and mortality in patients with ESRD.

Figures

Figure 1.

Participant flow. This figure highlights the number of participants who were approached, screened, included, randomized, and who completed the intervention.

Figure 2.

Model-adjusted mean change for the treatment and wait-list groups in phase 1. Treatment indicates group 1 participants, who received the intervention during this phase. Wait-list indicates group 2 participants, who received no intervention during this phase. Scales are presented so that the positive scores reflect improvement. The y-axis represents change scores for the individual measures.

Figure 3.

Model-adjusted mean change for the treatment and wait-list groups in phase 2. Follow-up indicates group 1 participants, who received no intervention during this phase. Delayed treatment indicates group 2 participants, who received the intervention during this phase. Scales are presented so that the positive scores reflect improvement. The y-axis represents change scores for the individual measures.

Figure 4.

Crossover study design. aParticipant information includes personal, ethnic, and demographic information, as well as information about mental health, substance use history and treatment, and mental status. bPsychological information includes BDI-II, HAM-D, KDQOL, SCID-I, and SCID-II. cMedical information includes presence of diabetes mellitus, hypertension, urea reduction ratio, serum albumin concentration, BUN concentration, creatinine concentration, calcium phosphate product, and IDWG.